BioMarin Pharmaceutical Inc. with ticker code (BMRN) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 185 and 70 with the average target price sitting at $116.52. Now with the previous closing price of $89.05 this would indicate that there is a potential upside of 30.8%. The day 50 moving average is $89.50 while the 200 day moving average is $96.52. The total market capitalization for the company now stands at 16.91B. The stock price is currently at: 89.87 USD
The potential market cap would be $22,128,055,194 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 172.83, revenue per share of 11.98 and a 0.91% return on assets.
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company’s portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin’s commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company’s clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.
